Cargando…
The impact of 10-valent pneumococcal vaccine introduction on invasive disease in Fiji
BACKGROUND: In 2012, Fiji introduced the 10-valent pneumococcal conjugate vaccine (PCV10). We assessed the impact of PCV10 on invasive pneumococcal disease (IPD), probable bacterial or pneumococcal meningitis (PBPM), meningitis and sepsis 3-5 years post-introduction. METHODS: Laboratory-confirmed IP...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8741523/ https://www.ncbi.nlm.nih.gov/pubmed/35028629 http://dx.doi.org/10.1016/j.lanwpc.2021.100352 |
_version_ | 1784629510330646528 |
---|---|
author | Reyburn, R. Tuivaga, E.J. Ratu, F.T. Dunne, E.M. Nand, D. Kado, J. Jenkins, K. Tikoduadua, L. Jenney, A. Howden, B.P. Ballard, S.A. Fox, K. Devi, R. Satzke, C. Rafai, E. Kama, M. Flasche, S. Mulholland, E.K. Russell, F.M. |
author_facet | Reyburn, R. Tuivaga, E.J. Ratu, F.T. Dunne, E.M. Nand, D. Kado, J. Jenkins, K. Tikoduadua, L. Jenney, A. Howden, B.P. Ballard, S.A. Fox, K. Devi, R. Satzke, C. Rafai, E. Kama, M. Flasche, S. Mulholland, E.K. Russell, F.M. |
author_sort | Reyburn, R. |
collection | PubMed |
description | BACKGROUND: In 2012, Fiji introduced the 10-valent pneumococcal conjugate vaccine (PCV10). We assessed the impact of PCV10 on invasive pneumococcal disease (IPD), probable bacterial or pneumococcal meningitis (PBPM), meningitis and sepsis 3-5 years post-introduction. METHODS: Laboratory-confirmed IPD and PBPM cases were extracted from national laboratory records. ICD-10-AM coded all-cause meningitis and sepsis cases were extracted from national hospitalisation records. Incidence rate ratios were used to compare outcomes pre/post-PCV10, stratified by age groups: 1-23m, 2-4y, 5-9y, 10-19y, 20-54y, ≥55y. To account for different detection and serotyping methods in the pre-and post-PCV10 period, a Bayesian inference model estimated serotype-specific changes in IPD, using pneumococcal carriage and surveillance data. FINDINGS: There were 423 IPD, 1,029 PBPM, 1,391 all-cause meningitis and 7,611 all-cause sepsis cases. Five years post-PCV10 introduction, IPD declined by 60% (95%CI: 37%, 76%) in children 1-23m months old, and in age groups 2-4y, 5-9y, 10-19y although confidence intervals spanned zero. PBPM declined by 36% (95%CI: 21%, 48%) among children 1-23 months old, and in all other age groups, although some confidence intervals spanned zero. Among children <5y of age, PCV10-type IPD declined by 83% (95%CI; 70%, 90%) and with no evidence of change in non-PCV10-type IPD (9%, 95%CI; -69, 43%). There was no change in all-cause meningitis or sepsis. Post-PCV10, the most common serotypes in vaccine age-eligible and non-age eligible people were serotypes 8 and 23B, and 3 and 7F, respectively. INTERPRETATIONS: Our study demonstrates the effectiveness of PCV10 against IPD in a country in the Asia-Pacific of which there is a paucity of data. FUNDING: This study was support by the Department of Foreign Affairs and Trade of the Australian Government and Fiji Health Sector Support Program (FHSSP). FHSSP is implemented by Abt JTA on behalf of the Australian Government. |
format | Online Article Text |
id | pubmed-8741523 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-87415232022-01-12 The impact of 10-valent pneumococcal vaccine introduction on invasive disease in Fiji Reyburn, R. Tuivaga, E.J. Ratu, F.T. Dunne, E.M. Nand, D. Kado, J. Jenkins, K. Tikoduadua, L. Jenney, A. Howden, B.P. Ballard, S.A. Fox, K. Devi, R. Satzke, C. Rafai, E. Kama, M. Flasche, S. Mulholland, E.K. Russell, F.M. Lancet Reg Health West Pac Article BACKGROUND: In 2012, Fiji introduced the 10-valent pneumococcal conjugate vaccine (PCV10). We assessed the impact of PCV10 on invasive pneumococcal disease (IPD), probable bacterial or pneumococcal meningitis (PBPM), meningitis and sepsis 3-5 years post-introduction. METHODS: Laboratory-confirmed IPD and PBPM cases were extracted from national laboratory records. ICD-10-AM coded all-cause meningitis and sepsis cases were extracted from national hospitalisation records. Incidence rate ratios were used to compare outcomes pre/post-PCV10, stratified by age groups: 1-23m, 2-4y, 5-9y, 10-19y, 20-54y, ≥55y. To account for different detection and serotyping methods in the pre-and post-PCV10 period, a Bayesian inference model estimated serotype-specific changes in IPD, using pneumococcal carriage and surveillance data. FINDINGS: There were 423 IPD, 1,029 PBPM, 1,391 all-cause meningitis and 7,611 all-cause sepsis cases. Five years post-PCV10 introduction, IPD declined by 60% (95%CI: 37%, 76%) in children 1-23m months old, and in age groups 2-4y, 5-9y, 10-19y although confidence intervals spanned zero. PBPM declined by 36% (95%CI: 21%, 48%) among children 1-23 months old, and in all other age groups, although some confidence intervals spanned zero. Among children <5y of age, PCV10-type IPD declined by 83% (95%CI; 70%, 90%) and with no evidence of change in non-PCV10-type IPD (9%, 95%CI; -69, 43%). There was no change in all-cause meningitis or sepsis. Post-PCV10, the most common serotypes in vaccine age-eligible and non-age eligible people were serotypes 8 and 23B, and 3 and 7F, respectively. INTERPRETATIONS: Our study demonstrates the effectiveness of PCV10 against IPD in a country in the Asia-Pacific of which there is a paucity of data. FUNDING: This study was support by the Department of Foreign Affairs and Trade of the Australian Government and Fiji Health Sector Support Program (FHSSP). FHSSP is implemented by Abt JTA on behalf of the Australian Government. Elsevier 2022-01-05 /pmc/articles/PMC8741523/ /pubmed/35028629 http://dx.doi.org/10.1016/j.lanwpc.2021.100352 Text en © 2021 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Article Reyburn, R. Tuivaga, E.J. Ratu, F.T. Dunne, E.M. Nand, D. Kado, J. Jenkins, K. Tikoduadua, L. Jenney, A. Howden, B.P. Ballard, S.A. Fox, K. Devi, R. Satzke, C. Rafai, E. Kama, M. Flasche, S. Mulholland, E.K. Russell, F.M. The impact of 10-valent pneumococcal vaccine introduction on invasive disease in Fiji |
title | The impact of 10-valent pneumococcal vaccine introduction on invasive disease in Fiji |
title_full | The impact of 10-valent pneumococcal vaccine introduction on invasive disease in Fiji |
title_fullStr | The impact of 10-valent pneumococcal vaccine introduction on invasive disease in Fiji |
title_full_unstemmed | The impact of 10-valent pneumococcal vaccine introduction on invasive disease in Fiji |
title_short | The impact of 10-valent pneumococcal vaccine introduction on invasive disease in Fiji |
title_sort | impact of 10-valent pneumococcal vaccine introduction on invasive disease in fiji |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8741523/ https://www.ncbi.nlm.nih.gov/pubmed/35028629 http://dx.doi.org/10.1016/j.lanwpc.2021.100352 |
work_keys_str_mv | AT reyburnr theimpactof10valentpneumococcalvaccineintroductiononinvasivediseaseinfiji AT tuivagaej theimpactof10valentpneumococcalvaccineintroductiononinvasivediseaseinfiji AT ratuft theimpactof10valentpneumococcalvaccineintroductiononinvasivediseaseinfiji AT dunneem theimpactof10valentpneumococcalvaccineintroductiononinvasivediseaseinfiji AT nandd theimpactof10valentpneumococcalvaccineintroductiononinvasivediseaseinfiji AT kadoj theimpactof10valentpneumococcalvaccineintroductiononinvasivediseaseinfiji AT jenkinsk theimpactof10valentpneumococcalvaccineintroductiononinvasivediseaseinfiji AT tikoduadual theimpactof10valentpneumococcalvaccineintroductiononinvasivediseaseinfiji AT jenneya theimpactof10valentpneumococcalvaccineintroductiononinvasivediseaseinfiji AT howdenbp theimpactof10valentpneumococcalvaccineintroductiononinvasivediseaseinfiji AT ballardsa theimpactof10valentpneumococcalvaccineintroductiononinvasivediseaseinfiji AT foxk theimpactof10valentpneumococcalvaccineintroductiononinvasivediseaseinfiji AT devir theimpactof10valentpneumococcalvaccineintroductiononinvasivediseaseinfiji AT satzkec theimpactof10valentpneumococcalvaccineintroductiononinvasivediseaseinfiji AT rafaie theimpactof10valentpneumococcalvaccineintroductiononinvasivediseaseinfiji AT kamam theimpactof10valentpneumococcalvaccineintroductiononinvasivediseaseinfiji AT flasches theimpactof10valentpneumococcalvaccineintroductiononinvasivediseaseinfiji AT mulhollandek theimpactof10valentpneumococcalvaccineintroductiononinvasivediseaseinfiji AT russellfm theimpactof10valentpneumococcalvaccineintroductiononinvasivediseaseinfiji AT reyburnr impactof10valentpneumococcalvaccineintroductiononinvasivediseaseinfiji AT tuivagaej impactof10valentpneumococcalvaccineintroductiononinvasivediseaseinfiji AT ratuft impactof10valentpneumococcalvaccineintroductiononinvasivediseaseinfiji AT dunneem impactof10valentpneumococcalvaccineintroductiononinvasivediseaseinfiji AT nandd impactof10valentpneumococcalvaccineintroductiononinvasivediseaseinfiji AT kadoj impactof10valentpneumococcalvaccineintroductiononinvasivediseaseinfiji AT jenkinsk impactof10valentpneumococcalvaccineintroductiononinvasivediseaseinfiji AT tikoduadual impactof10valentpneumococcalvaccineintroductiononinvasivediseaseinfiji AT jenneya impactof10valentpneumococcalvaccineintroductiononinvasivediseaseinfiji AT howdenbp impactof10valentpneumococcalvaccineintroductiononinvasivediseaseinfiji AT ballardsa impactof10valentpneumococcalvaccineintroductiononinvasivediseaseinfiji AT foxk impactof10valentpneumococcalvaccineintroductiononinvasivediseaseinfiji AT devir impactof10valentpneumococcalvaccineintroductiononinvasivediseaseinfiji AT satzkec impactof10valentpneumococcalvaccineintroductiononinvasivediseaseinfiji AT rafaie impactof10valentpneumococcalvaccineintroductiononinvasivediseaseinfiji AT kamam impactof10valentpneumococcalvaccineintroductiononinvasivediseaseinfiji AT flasches impactof10valentpneumococcalvaccineintroductiononinvasivediseaseinfiji AT mulhollandek impactof10valentpneumococcalvaccineintroductiononinvasivediseaseinfiji AT russellfm impactof10valentpneumococcalvaccineintroductiononinvasivediseaseinfiji |